Last updated 18 October 2026. uniQure’s four-year Huntington’s data missed significance on the composite scale, while FUS-ALS gained a positive Phase 3 result.
The neurodegeneration pipeline entered the autumn of 2026 looking very different from the one that opened the year. Two events in the first week of September made the shift explicit. The US Food and Drug Administration approved the first treatment for a rare astrocyte disorder. A day earlier, uniQure announced US and UK filings for a Huntington’s disease gene therapy. Neither product targets amyloid. Both work by silencing a gene.
The weeks since then have tested that reading. A genetically targeted ALS drug met its Phase 3 primary endpoint. The Huntington’s gene therapy missed significance on its prespecified composite measure at four years. Parkinson’s disease gained a newly approved symptomatic drug and a positive Phase 3 symptomatic readout. Disease modification in common neurodegeneration remains out of reach.
At a glance: key neurodegeneration catalysts
The table lists neurodegeneration pipeline milestones that sponsors have publicly guided.
| Asset | Sponsor | Indication | Next milestone | Timing as guided by sponsor |
| Ifezuntirgene inilparvovec (AMT-130) | uniQure | Huntington’s disease | FDA decision on accepting the BLA; priority review requested | 60-day filing review from the 2 September 2026 submission |
| Ulefnersen | Otsuka, with Ionis | FUS-ALS | Review of FUSION results with the FDA; full data at a medical congress | Publication “in the coming months” |
| Tavapadon (Juvmo) | AbbVie | Parkinson’s disease | US availability | October 2026 |
| Solengepras | Cerevance | Parkinson’s disease | FDA meeting on next steps toward a potential NDA | Not disclosed |
| MN-166 (ibudilast) | MediciNova | ALS | COMBAT-ALS double-blind topline results | By the end of 2026 |
| Zilganersen (Zanvastro) | Recordati (outside the US) | Alexander disease | Regulatory submissions in Europe and Japan | 2027 |
A first approval in Alexander disease
On 3 September 2026, the FDA approved Zanvastro (zilganersen) for Alexander disease in paediatric and adult patients. The FDA describes it as the first approved treatment for the condition. The agency also calls it the first therapy “to directly target the protein buildup that drives the disease”. Until now, care had been limited to managing symptoms.
Alexander disease is caused by mutations in the GFAP gene. These trigger the overproduction and toxic accumulation of glial fibrillary acidic protein in astrocytes. Ionis estimates that the disorder affects roughly one in one to three million people worldwide. Zanvastro is an RNA-targeted medicine that reduces GFAP production. The 50 mg dose is given quarterly by intrathecal injection.
The approval rested on the pivotal Phase 1-3 study. It met its primary endpoint in participants aged five and above. The 50 mg dose delivered a statistically significant stabilisation of gait speed on the 10-metre walk test. The least squares mean difference at week 61 was 33.3 per cent against control (P = .041).
Children aged two to four also improved on a broader gross motor measure. The most common adverse reactions were vomiting, back pain, cough, headache and post-lumbar puncture syndrome. Aseptic meningitis has been reported and appears in the warnings section of the label.
Ionis describes Zanvastro as its first independent launch from its neurology pipeline. Ionis also received a rare paediatric disease priority review voucher alongside the approval. Recordati holds rights outside the United States under a June 2026 licence. Submissions in Europe and Japan are expected in 2027.
Huntington’s disease reaches the regulators
Huntington’s disease is now one of the most closely watched filings in the neurodegeneration pipeline. On 2 September 2026, uniQure announced it had submitted a Biologics License Application to the FDA, seeking accelerated approval. The application covers ifezuntirgene inilparvovec, previously known as AMT-130. A Marketing Authorisation Application went to the UK’s Medicines and Healthcare products Regulatory Agency on the same day.
The therapy uses an AAV5 vector carrying a microRNA designed to silence the huntingtin gene. It is given once, by MRI-guided convection-enhanced stereotactic delivery into the caudate and putamen. Both filings rest on three-year Phase I/II data. Those data were compared with a propensity score-matched external control drawn from the Enroll-HD natural history dataset.
The prespecified primary measure was the composite Unified Huntington’s Disease Rating Scale, or cUHDRS. uniQure said in December 2024 that the FDA had agreed cUHDRS may be used as an intermediate clinical endpoint. In an updated 36-month analysis, the high dose showed 80 per cent slowing on that scale (nominal P = .005). Cerebrospinal fluid neurofilament light chain was 6 per cent below baseline at 36 months. Matt Kapusta, chief executive officer at uniQure, called the submissions “an important milestone for the Huntington’s disease community”.
The regulatory path was not smooth. The FDA changed position more than once during the past year. It eventually agreed in June 2026 that the three-year analysis could serve as primary evidence. uniQure has requested priority review. A search on 18 October 2026 found no announcement on whether the FDA had accepted the application for review. No MHRA validation had been announced either.
Four-year data miss on the composite scale
uniQure reported four-year results on 29 September 2026. Twelve high-dose patients reached 48 months. Slowing on the cUHDRS was 44 per cent against an updated external control. The p-value was 0.144, so the prespecified primary measure did not reach statistical significance. Total Functional Capacity showed 61 per cent slowing (nominal P = .008).
A post hoc analysis against the earlier external control gave 53.5 per cent cUHDRS slowing (nominal P = .041). Cerebrospinal fluid neurofilament light chain was 4 per cent above baseline at 48 months. Five high-dose participants, or 17 per cent, had a treatment-related serious adverse event involving central nervous system inflammation. All fully resolved. One suicide in a low-dose participant was assessed by the investigator as unrelated to treatment.
The four-year data were not part of the application, which rests on the three-year analysis. A full breakdown of the AMT-130 four-year data sets out the external control method and its missing data.
Durability remains the central open question, since a single administration must hold its effect for decades. The four-year composite result sharpens that question rather than settling it. The long-term risk of intracranial delivery in an ambulatory population is the other.
What the neurodegeneration pipeline lost in Alzheimer’s disease
These gains arrived alongside a run of well-publicised failures. Novo Nordisk reported in November 2025 that oral semaglutide missed its primary endpoint. The evoke and evoke+ trials enrolled 3,808 adults aged 55 to 85. All had mild cognitive impairment or mild dementia with confirmed amyloid positivity. Biomarkers improved. Progression on the Clinical Dementia Rating Sum of Boxes did not slow.
Martin Holst Lange is chief scientific officer at Novo Nordisk. He said the company “had a responsibility to explore semaglutide’s potential, despite a low likelihood of success”. The one-year extension periods in both trials were discontinued.
Johnson & Johnson stopped its AuTonomy study of the tau antibody posdinemab on 21 November 2025. A scheduled review found that the proof-of-concept study did not significantly slow clinical decline in early Alzheimer’s disease.
Tau itself has not left the neurodegeneration pipeline. The Phase 2 CELIA data reported in July 2026 missed the primary endpoint for diranersen. Prespecified secondary endpoints still showed tau reduction and slowed clinical decline. Biogen plans to advance diranersen into confirmatory Phase 3 development but has not given timing. The Alzheimer’s Drug Discovery Foundation has made the wider point. In May 2026 it said 75 per cent of current Alzheimer’s trials target pathways beyond amyloid and tau.
Parkinson’s disease: better symptom control, no disease modification yet
Parkinson’s disease sits at the other end of the neurodegeneration pipeline. The period brought an approval and a positive Phase 3 readout, both for symptom control.
Tavapadon approved as Juvmo
The FDA approved tavapadon on 25 September 2026, according to its list of novel drug approvals. AbbVie announced the approval under the brand name Juvmo on 28 September 2026. The approved use is to treat Parkinson’s disease in adults. It is taken once daily, with or without levodopa. AbbVie describes it as the first selective D1/D5 receptor agonist approved for the condition. The company expected US availability in October 2026.
In the TEMPO-3 trial, adding Juvmo to levodopa increased daily on-time without troublesome dyskinesia by 1.7 hours. The placebo group gained 0.6 hours (P < .0001). Off-time fell by 1.9 hours against 0.9 hours (P = .0006). With levodopa, the most common adverse events included nausea, dyskinesia, dizziness, headache, hallucinations and orthostatic hypotension. AbbVie’s safety information warns of low blood pressure, hallucinations, dyskinesia and unusual urges.
On 7 October 2026, Cerevance reported that once-daily oral solengepras met the primary endpoint of its Phase 3 ARISE trial. The trial enrolled 341 people already taking levodopa and other Parkinson’s medicines. The 150 mg dose cut average daily off-time by 0.61 hours against placebo at week 12 (P = .035).
Solengepras inhibits the GPR6 receptor and has no direct effect on dopamine receptors. Headache, urinary tract infection, insomnia and nausea were more common than with placebo. Dyskinesia occurred in 4.4 per cent of patients on 150 mg and 1.8 per cent on placebo. Cerevance plans to meet the FDA to discuss next steps toward a potential New Drug Application. Fuller ARISE results were presented at the International Congress of Parkinson’s Disease and Movement Disorders on 12 October 2026.
Disease modification has proved harder. Roche began the Phase 3 PARAISO trial of the anti-alpha-synuclein antibody prasinezumab in the fourth quarter of 2025. It plans to enrol about 900 people. BlueRock’s stem cell therapy bemdaneprocel entered Phase 3 in September 2025. Neither has reported.
Biogen and Denali discontinued the LRRK2 inhibitor BIIB122 for idiopathic Parkinson’s disease in May 2026. The Phase 2b LUMA trial had missed its primary endpoint. Denali continues a separate Phase 2a study, BEACON, in people with LRRK2-associated Parkinson’s disease.
Motor neurone disease: a genetic subset reaches Phase 3 success
Motor neurone disease produced the clearest recent result for genetic medicine in the neurodegeneration pipeline. On 22 September 2026, Ionis and Otsuka reported positive topline results from the FUSION study of ulefnersen. The companies call FUSION a Phase 3 study, within a Phase 1-3 trial design. The antisense drug targets FUS-ALS, a genetically defined subset of a heterogeneous condition. Otsuka licensed ulefnersen from Ionis in 2024.
The primary endpoint was a joint rank analysis of survival, permanent ventilation, rescue and change in ALSFRS-R score. The companies reported a statistically significant improvement against placebo (P = .0005) in a primary analysis population of 73. They did not disclose effect sizes or results for the individual components. The release said serum neurofilament light chain and an event-based secondary endpoint also improved significantly. No values were given.
The companies described a “favorable safety and tolerability profile”, with most adverse events mild or moderate. No adverse event rates were published. Otsuka plans to review the results with the FDA. Otsuka also opened a global early access programme on the same day. Ulefnersen is not yet approved by any regulator. Detailed data are due at a future medical congress. A separate report examines the FUS-ALS treatment result and its unpublished figures.
Sporadic ALS has a nearer catalyst in the neurodegeneration pipeline. On 24 September 2026, MediciNova announced the last patient visit in the double-blind portion of its Phase 2b/3 COMBAT-ALS trial. The trial tests MN-166 (ibudilast). MediciNova expects topline results by the end of 2026.
The UK access problem
Approval and access are not the same thing. NICE published final draft guidance rejecting lecanemab and donanemab for NHS use in June 2025. Its committee judged the benefits too small to justify the additional cost to the NHS.
Appeal panels upheld several grounds, with the lecanemab appeal decision dated 20 March 2026. A third draft guidance consultation then ran from 31 March to 28 April 2026. The reconvened committee met on 8 July 2026. Eisai has accepted the committee’s assumptions as the basis for commercial talks with NHS England. Lilly had not done so by late July and said it was “considering all options”.
A check of both NICE project pages on 18 October 2026 found no publication date set for either appraisal.
The wider policy picture is more encouraging. The government has committed to publishing a modern service framework for dementia and frailty by the end of 2026. It also planned an interim product for September 2026 to feed into NHS and local government planning. A search on 18 October 2026 did not find a published interim product. Diagnostic infrastructure remains the binding constraint. One in six UK hospital beds is occupied by a person with dementia. A UCL review published in August 2026 projects one in four by 2040.
That gap matters now that the neurodegeneration pipeline is filing in Britain. uniQure’s MHRA application will eventually meet the same health technology assessment machinery. A single-administration gene therapy poses an unfamiliar problem for appraisal models built around annual treatment costs.
What comes next
Across the neurodegeneration pipeline, genetic and monogenic indications have been advancing faster than common heterogeneous diseases. That is the thesis of this analysis. The evidence since the September edition mostly supports it, with one important qualification.
It held in motor neurone disease. Ulefnersen met its Phase 3 primary endpoint in a genetically defined ALS subset. In common disease, the period again produced symptomatic advances rather than disease modification. Juvmo and solengepras both target motor symptoms in Parkinson’s disease. Neither is described by its sponsor as slowing the disease.
The qualification is Huntington’s disease. A known causal gene did not guarantee statistical separation on the prespecified composite measure at four years. That result rests on 12 patients and an external control with rising missing data. It does show that a genetically validated target is not the same as proof of lasting benefit.
The headline therefore stands for now. Genetic medicine still leads the neurodegeneration pipeline on approvals and positive pivotal data. The next tests for the neurodegeneration pipeline are concrete. They include the FDA filing decision on ifezuntirgene inilparvovec, the ulefnersen regulatory discussions and the COMBAT-ALS readout. Whether payers can absorb one-time therapies priced for very small populations remains the question after that.
